Eyenovia (NASDAQ:EYEN) is set to post its quarterly earnings results before the market opens on Tuesday, May 14th. Analysts expect Eyenovia to post earnings of ($0.51) per share for the quarter.
Eyenovia (NASDAQ:EYEN) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.17). On average, analysts expect Eyenovia to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Eyenovia stock opened at $6.00 on Tuesday. Eyenovia has a 12-month low of $2.40 and a 12-month high of $8.96. The stock has a market cap of $72.12 million, a price-to-earnings ratio of -3.30 and a beta of 1.68.
EYEN has been the topic of several research analyst reports. Zacks Investment Research cut shares of Eyenovia from a “hold” rating to a “sell” rating in a research report on Tuesday, March 12th. HC Wainwright set a $14.00 target price on shares of Eyenovia and gave the stock a “buy” rating in a research report on Tuesday, February 26th. Finally, Oppenheimer initiated coverage on shares of Eyenovia in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $9.00 target price on the stock.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Further Reading: Beige Book
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.